Tags

Bispecific antibody 6MW5311

China's NMPA clears Mabwell's bispecific antibody 6MW5311 for clinical trials

China's NMPA clears Mabwell's bispecific antibody 6MW5311 for clinical trials

June 24, 2026 | 09:48
China's National Medical Products Administration has cleared the clinical trial application for Mabwell's innovative LILRB4/CD3-targeting bispecific antibody 6MW5311, advancing the company's oncology pipeline.

Latest News

NYSE Content Update: FIRY Announces Rebranding From Skillz Inc.

NYSE Content Update: FIRY Announces Rebranding From Skillz Inc.

Moka AI launches Eva recruiting agent for enterprise hiring teams across Asia Pacific

Moka AI launches Eva recruiting agent for enterprise hiring teams across Asia Pacific

Zafin launches AIOS platform to govern agentic AI for regulated financial institutions

Zafin launches AIOS platform to govern agentic AI for regulated financial institutions

GCL SI adopts back-contact cell technology as core strategy at Intersolar 2026

GCL SI adopts back-contact cell technology as core strategy at Intersolar 2026

Vietnam Investment Review under the Ministry of Finance

Editor-in-Chief: Pham Van Hoanh

Deputy Editors-in-Chief: Le Trong Minh, Ngo Chi Tung, Nguyen Van Hong

Managing Editor: Nguyen Chi Mai

Advertisement  | Contact us

Based on MasterCMS Ultimate Edition 2026 v2.9
Corporate CEO Talk Biz Link PR Newswire Media OutReach Newswire
Investing M&A Outbound Investment Investing in Haiphong
Your Consultant KPMG PwC Indochine Counsel Vilasia
Green Growth Energy Efficiency Rethinking Plastics BASF
Property Green Buildings Industrial Properties
Money Insurance Smart Payment Trends Stock Monitor
Infographics
Timeout Travel Hotels & Restaurants The Insider Entertainment Lifestyle
Sports
Photos
Society Swing for the Kids CSR
World News
virs-publications-vir
timeout-vn
ptbv2020